X

Trial Profile

A Phase I/II trial of LTX-401 for treatment of visceral tumors

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 04 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LTX-401 (Primary)
Indications Tumours
Focus Adverse reactions; Therapeutic Use

Most Recent Events

31 Aug 2023 According to a Lytix Biopharma media release, the company made decision to refocus resources and generate additional clinical efficacy data on LTX-315, resulting in the postponement of the start of this trial.
11 May 2023 According to a Lytix Biopharma media release, preparations for submission of Clinical Trial Application (CTA) required to start this study is ongoing.
17 Nov 2022 According to a Lytix Biopharma media release, IND enabling activities required to start the study are progressing as planned.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com